Cheng Liu, PhD

Founder & CEO

Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

MDC photo 100723

Michael D. Cannon

Board of Directors

Mr. Cannon brings over four-decades of intensive experience in the healthcare industry, serving as senior management and board member of a wide range of companies. He currently sits on the boards of Antiva Biosciences, BioSentinel, Moleculin and Osel. From 1983 to 2004, Mr. Cannon worked at SICOR, Inc., a generic manufacturer corticosteroids, anti-cancer drugs and anesthetics in the roles of Head of Business Development, Chief Scientific Officer, and later Executive Vice President. From 1997 SICOR’s share value on the NASDAQ increased nearly seven-folded until the company was sold to TEVA in 2004. Mr. Cannon was also a director of Metabasis, a California biotechnology company specializing in metabolic diseases of the liver, diabetes and cancer prior to its IPO in 2005.
Mr. Cannon received his B.S. in Chemistry from Fordam College.

Sandy Chau, MBA Board of Directors

Sandy Chau, MBA

Board of Directors

Wai-Yan “Sandy” Chau is the Founder and President of Trident USA, a diversified holding company that invests in real estate and provides venture capital throughout Greater China and the United States. As a Hua Yuan “Angel,” Mr. Chau has been an active investor in several companies started by Hua Yuan members including: Achievo, Viador, Servgate, Photonify, EnReach, and Televigation. Prior to Trident USA, Mr. Chau actively invested in real estate and provided venture capital in Taiwan, China, and the US. He served as Chairman of CITIC Shenzhen Properties from 1994 – 1997 and President of Pacific Constructions from 1992 – 1995, one of the largest public real estate development companies traded publicly in Taiwan. Before real estate, Mr. Chau was a successful technology entrepreneur, founding Universal Semiconductor and running the company as its CEO.

Mr. Chau was born in Shanghai and was raised in Hong Kong and Vietnam. He received his B.S. from the University of California, Berkeley and an MBA.

C. K. Cheng, MBA Board of Directors

C. K. Cheng, MBA

Board of Directors

Mr. Cheng is co-founder and General Partner of Harbinger Venture, a pan-Pacific venture capital firm actively investing in US, Taiwan, and China. Mr. Cheng currently sits on the boards of Applied Optoelectronics Inc., Cardiva, Envivio, Eureka Therapeutics, General Photonics, and Quintic. His previous investments include Actrans (acquired by SSTI), Arques (acquired by California Micro Devices), Celestry (acquired by Cadence), Centrality (acquired by SiRF), Paxera (acquired by NeoPhotonics), Plaxo (acquired by Comcast), Synnex (listed in NYSE), and Tasman Networks (acquired by Nortel). Prior to founding Harbinger Venture in 2000 with the anchor investment from MiTAC/Synnex Group, Mr. Cheng was Senior Vice President of Product Marketing at Synnex (NYSE:SNX). During his 8-year tenure with Synnex, he held various management responsibilities including product line management, engineering, manufacturing operations, new business development, and corporate development.

In 2007, Mr.Cheng was Chairman of the Monte Jade Science and Technology Association, an association for Chinese technology and business professionals in the Bay Area. He also writes regularly for several magazines on business trends and philosophy.

Mr. Cheng received his MBA from National Chiao-Tung University, Taiwan, and B.S.in Physics from National Tsing-Hua University, Taiwan.

Hsing Kung, PhD Board of Directors

Hsing Kung, PhD

Board of Directors

Dr. Kung is a partner of Acorn Campus Ventures and Chairman of Luxnet Corporation. He co-founded Pine Photonics in 2000 and served as President/CEO until the merger with Opnext. He then served as Sr. VP of Opnext Inc until 2005. Dr. Kung co-founded SDL Inc. and served as their VP of manufacturing from 1983 to 1997. In recent years, he has devoted his efforts to promote Chinese-American participation in community activities. He formerly served as a board member of the Fremont Union High School District Board. During his tenure, he made significant contributions promoting a multi-cultural climate in high schools. Currently, Dr. Kung serves on the United Way Silicon Valley and American Leadership Forum Silicon Valley boards.

In 1997, he was awarded the Distinguished Alumni Award from the North American National Cheng Kung University Alumni Association. In March 2001, he received a Partnering for Education award from The National Council of Negro Women, Northern California Section. In December, 2001, Dr. Kung and his wife Margaret received the “Venture Culturists” award from DeAnza College. In 2002, he received the “Asian American Hero” award from the County of Santa Clara. In 2004, he received the “Community Star Award” from Asian Americans for Community Involvement, and “Helen Tao Activist of the Year” Award from the Silicon Valley APA Democratic Club.

Dr. Kung holds a BS from the National Cheng Kung University, PhD from the University of California at Berkeley, and MBA from Santa Clara University.

Acorn Campus Ventures

Acorn Campus Ventures is a venture fund that provides incubation facilities and infrastructure to emerging companies. Acorn focuses on the wireless, semiconductor, photonics, communications, internet and life science fields, and has established a network between the academic and business community across the Pacific Rim region. The fund has offices in Silicon Valley, Shanghai and an affiliate office in Taipei.

Qiushi Fu copy

Qiushi Fu, PhD, MBA

Board of Directors

Dr. Fu is managing director of Yuan Capital, a private equity firm focused on world-class investment opportunities, covering healthcare, technology and finance, with a strong emphasis on China. Prior to that, Dr. Fu worked at DaChen Capital, a top tier venture capital fund in China, from 2007 to 2013 leading its healthcare sector. During his career at DaChen Capital, he participated in the investment of over 20 companies, most of which have either been listed on China’s A-share market or have already passed China SRC pre-qualification. Dr. Fu started his scientific career at Roche Diagnostics, followed by SiBiono GeneTech from 2003 to 2007.

Dr. Fu received his PhD in Developmental Biology from the University of Illinois at Urbana-Champaign, and his B.A. & M.S. in Molecular Biology from Peking University. He received his EMBA in techno-entrepreneurship from the London Business School, funded by the British Council’s Chevening Scholarship.

Yuan Capital

Yuan Capital is a private equity firm with offices in Beijing and Hong Kong. It focuses on world-class investment opportunities with a strong emphasis on China. Founded by seasoned investors and renowned business leaders, Yuan Capital leverages its deep expertise and network to help companies worldwide become successful in the region. The firm has invested in many leading players in a variety of sectors including technology, healthcare and finance.

Bruce Ames

Professor Bruce Ames, PhD

Co-chair, Scientific Advisory Board

Dr. Ames is a Professor of Biochemistry and Molecular Biology, University of California, Berkeley. Dr. Ames is well-known for his invention of the Ames Test, a biological assay to assess the mutagenic potential of chemical compounds. He currently serves on the Commission on Life Sciences for the National Academy of Sciences and was a member of the board of directors of the National Cancer Institute from 1976 to 1982. He was the recipient of the General Motors Cancer Research Foundation Prize (1983), the Tyler Environmental Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize awarded by the Japanese Emperor , (1997), the Kehoe Award, American College of Occupational And Environmental Medicine (1997), the Medal of the City of Paris (1998), the U.S. National Medal of Science awarded by President Clinton(1998), the Linus Pauling Institute Prize for Health Research (2001), and the American Society for Microbiology Lifetime Achievement Award (2001). He has contributed to over 450 publications and is one of the most-cited scientists in all fields.


Nai-Kong V. Cheung, MD, PhD

Member, Scientific Advisory Board

Dr. Cheung and Eureka have been closely working together on multiple collaboration projects since 2007. Dr. Cheung, Enid A. Haupt Endowed Chair in Pediatric Oncology at Memorial Sloan-Kettering Cancer Center, New York, NY, received his B.Sc. degree from the University of Chicago, as well as MD and PhD in Immunology from Harvard Medical School. He studied suppressor T cells and B cell tolerance under the mentorship of Dr. Baruj Benacerraf, the 1980 Nobel Laureate in Medicine. Upon completing pediatric training in Pediatrics and Pediatric Hematology/Oncology at Stanford University Medical Center, Dr. Cheung has devoted his career to translational science with a clinical focus on neuroblastoma, and a research focused on antibody-based therapies. His work has changed the outlook for children with high-risk metastatic neuroblastoma, including those with central nervous system metastases. His current research is directed at target discovery, antibody humanization and engineering, as well as novel platform technologies tailored for fast clinical translation for cancers in children and young adults.


Professor Hsing-Jien Kung, PhD

Co-chair, Scientific Advisory Board

Dr. Kung is the current president of Taiwan National Health Research Institute. He was professor in Biological Chemistry at the University of California at Davis, School of Medicine. He is also the Director of Basic Science Research at the UC Davis Cancer Center. Dr. Kung is an internationally known scientist and cancer researcher. His current major research interests include signal transduction, oncogenes, tyrosine kinases, prostate cancer and cancer virology. Dr. Kung earned his Ph.D. from the California Institute of Technology in 1976, and his B.S. in Chemistry from the National Taiwan University in 1969.


Professor Peter Lee, MD

Member, Scientific Advisory Board

Dr. Lee is currently Chair of Cancer Immunotherapeutics & Tumor Immunology at City of Hope. His research focuses on understanding the biology of the immune response to cancer. Dr. Lee’s research seeks to establish how the immune system distinguishes between a normal cell and a cancer cell, the molecular mechanisms by which cancer cells modulate the immune response. Dr. Lee was the recipient of the Era of Hope Award for breast cancer research in 2006.


David A. Scheinberg, MD, PhD

Member, Scientific Advisory Board

Dr. Scheinberg is currently Vincent Astor Chair and Chairman, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute; Chairman, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC.  As a physician-scientist, Dr. Scheinberg specializes in the care of patients with leukemia. He investigates new therapeutic approaches to cancer, both in the hospital and in the laboratory. The focus of his research is the discovery and development of novel, specific immunotherapeutic agents.  Eight different therapeutic agents developed by Dr. Scheinberg’s laboratory have reached human clinical trials, which include the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, the first tumor specific fusion oncogene product vaccines, and antibodies to intracellular proteins. Dr. Scheinberg has published more than 280 papers, chapters, or books in these fields.  Dr. Scheinberg received his bachelor’s degree from Cornell University and his M.D. degree and Ph.D. degree in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.